Get started

Financials · BGLC

BioNexus Gene Lab Corp (BGLC) financials

For the twelve months ended Jun 30, 2026, BioNexus Gene Lab Corp reported $3.13M of revenue and -$2.58M of net income.

Revenue, TTM
$3.13M
Revenue growth, YoY
-67.3%
Net income, TTM
-$2.58M
Net margin
-82.4%
Free cash flow, TTM
-$853.6K
Cash
$1.23M
P/S
0.84
Market cap
$2.6M
Annual revenue$7.42M
FY2018FY2025
Annual net income-$2.98M
FY2018FY2025
Annual free cash flow-$1.88M
FY2018FY2025

BGLC revenue and earnings growth

BGLC revenueQ2 2026$76.2K

Quarter YoY
-96.6%
QoQ
+233.4%
FY YoY
-21.9%
5Y CAGR
-8.2%

BGLC revenue was $76.2K in fiscal Q2 2026 (ended Jun 30, 2026), down 96.6% from a year earlier and up 233.4% from the prior quarter. For the full fiscal 2025 it was $7.42M, down 21.9% from fiscal 2024. Compound annual growth was -8.2% over 5 years. It rose in 2 of the last 7 fiscal years.

BGLC net incomeQ2 2026-$286.5K

BGLC net income was -$286.5K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$616.2K a year earlier. For the full fiscal 2025 it was -$2.98M, compared with -$1.60M in fiscal 2024.

BGLC EPSQ2 2026-$0.12

BGLC diluted EPS was -$0.12 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.34 a year earlier. For the full fiscal 2024 it was -$0.09, compared with -$0.17 in fiscal 2023.

BGLC free cash flowQ2 2026-$422.7K

BGLC free cash flow was -$422.7K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$759.4K a year earlier. For the full fiscal 2025 it was -$1.88M, compared with -$2.32M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Revenue$7.42M$9.51M$9.77M$10.93M$13.36M$11.39M$127.0K$212.3K
Cost of revenue$6.34M$8.22M$8.44M$9.67M$11.10M$9.67M$71.1K-$183.6K
Gross profit$1.09M$1.29M$1.33M$1.26M$2.27M$1.72M$55.9K$28.8K
Research and development$50.7K$47.5K$55.0K-----
Selling, general and admin$1.54M$1.83M$2.44M$1.73M$1.28M$1.33M$356.6K-$241.9K
Operating income-$2.97M-$1.57M-$2.59M-$291.2K$1.06M$1.27M-$275.7K$59.9K
Interest expense--$13.9K$12.5K----
Pre-tax income-$2.98M-$1.59M-$2.61M-$303.7K$1.04M---
Income tax$0-$3.5K-$21.5K-$52.3K-$291.3K-$24.8K-$33.4K
Net income-$2.98M-$1.60M-$2.63M-$356.0K$751.6K$1.09M-$246.5K$26.5K
EPS, basic-----$0.01$0.00$0.00
EPS, diluted--$0.09-$0.17--$0.01$0.00$0.00
Diluted shares-17.8M15.9M--102.9M86.4M66.3M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Cash and equivalents$2.38M$2.89M$4.52M$2.12M$2.12M$2.79M$859.1K$1.26M
Receivables$505.9K$1.38M------
Inventory$676.7K$1.39M$1.14M$977.8K$1.52M$1.18M$7.6K$15.3K
Current assets$5.45M$7.43M$8.05M$6.02M$7.15M$7.99M$882.6K$1.30M
Total assets$9.25M$10.43M$11.40M$8.74M$9.57M$10.12M$1.23M$1.65M
Current liabilities$521.0K$1.95M$1.63M$2.00M$2.33M$3.37M$51.6K$62.9K
Total liabilities$637.9K$2.11M$1.74M$2.08M$2.39M$3.45M$108.9K$130.3K
Shareholders' equity$8.61M$8.32M$9.66M$6.67M$7.18M$6.66M$1.12M$1.52M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Operating cash flow-$1.84M-$2.09M-$1.82M$551.8K$9.2K$552.7K-$217.3K-$274.1K
Capital expenditures$37.0K$227.0K$149.4K$0$3.2K$421.6K$12.8K-$39.6K
Free cash flow-$1.88M-$2.32M-$1.97M$551.8K$6.0K$131.1K-$230.1K-$313.7K
Investing cash flow$944.8K$418.2K-$1.79M-$450.5K-$490.6K$1.32M-$12.8K-$51.7K
Financing cash flow$298.8K$4.0K$6.27M$108.2K-$28.2K-$4.9K-$180.8K$742.9K
Stock-based compensation$794.8K$141.0K------
Depreciation and amortization------$41.7K$40.6K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Revenue growth, YoY-21.9%-2.7%-10.6%-18.2%17.3%8872.0%-40.2%-
Net income growth, YoY-----31.3%---
Gross margin14.6%13.6%13.6%11.5%17.0%15.1%44.0%13.5%
Operating margin-39.9%-16.5%-26.5%-2.7%7.9%11.2%-217.2%28.2%
Net margin-40.2%-16.8%-26.9%-3.3%5.6%9.6%-194.1%12.5%
Free cash flow margin-25.3%-24.4%-20.2%5.0%0.0%1.2%-181.2%-147.7%
Return on equity-34.6%-19.2%-27.2%-5.3%10.5%16.4%-22.0%1.7%
Return on assets-32.3%-15.3%-23.1%-4.1%7.8%10.8%-20.0%1.6%
Current ratio10.463.814.933.003.072.3717.1120.64

Source: XBRL data BioNexus Gene Lab Corp files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

BGLC peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
BGLC$3.13M-67.3%-$2.58M-82.4%$2.6M
UNH$449.66B+3.3%$15.88B3.5%$356.28B
ELV$201.83B+3.6%$5.13B2.5%$90.37B
CI$286.32B+6.8%$5.99B2.1%$77.89B
HUM$154.19B+22.0%$1.25B0.8%$50.82B
NTRA$2.91B+37.4%-$164.71M-5.7%$46.46B
CNC$203.90B+9.7%$1.46B0.7%$33.93B
ILMN$4.54B+5.8%$895.00M19.7%$33.38B
LH$14.59B+6.0%$1.00B6.9%$30.19B

BGLC FAQ

8 questions
  • What is BGLC revenue?
    BioNexus Gene Lab Corp (BGLC) reported $3.13M of revenue for the twelve months ended Jun 30, 2026. That is down 67.3% from the year before. Revenue for fiscal 2025 was $7.42M.
  • Is BGLC profitable?
    No. BioNexus Gene Lab Corp reported a net loss of $2.58M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does BGLC have?
    BioNexus Gene Lab Corp reported $1.23M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is BGLC revenue growing?
    BioNexus Gene Lab Corp's revenue changed -21.9% in fiscal 2025, to $7.42M. Its compound annual growth rate was -8.2% over 5 years.
  • What is BGLC gross margin?
    BioNexus Gene Lab Corp's gross profit was $385.9K on $3.13M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 12.3%.
  • What is BGLC free cash flow?
    BioNexus Gene Lab Corp generated -$853.6K of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$846.6K less capital expenditures.
  • When did BGLC last report financial results?
    The latest statements here come from BioNexus Gene Lab Corp's 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.
  • Where does this BGLC financial data come from?
    Quantisnow builds these statements from the structured XBRL data BioNexus Gene Lab Corp files with the SEC. It is provided for information only and is not investment advice.